Showing 2511-2520 of 5771 results for "".
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Johnson & Johnson Vision Announces Launch of Elita Platform to Correct Myopia with New SILK Procedurehttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-elita-platform-to-correct-myopia-with-new-silk-procedure/2481802/Johnson & Johnson Vision will launch the new Elita Platform at European Society of Cataract and Refractive Surgeons (ESCRS) Congress, September 8-12, 2023, in Vienna, Austria. The Elita Platform enables surgeons to perform refractive correction on patients w
- Sandoz Announces Results from Mylight Phase 3 Study for Biosimilar Aflibercepthttps://modernod.com/news/sandoz-announces-results-from-mylight-phase-3-study-for-biosimilar-aflibercept/2481777/Sandoz released positive results from the MYLIGHT phase 3 confirmatory efficacy and safety study for its biosimilar aflibercept for wet macular degeneration (AMD). The Mylight phase 3 confirmatory efficacy and safety study (ClinicalTrials.gov NCT04864834) met its pri
- iHealthScreen Announces FDA 510(k) Submission for iPredict Automated AI-Based AMD Toolhttps://modernod.com/news/ihealthscreen-announces-fda-510k-submission-for-ipredict-automated-ai-based-amd-tool/2481632/iHealthScreen has submitted for FDA 510(k) clearance for iPredict, making it the first company to apply for an FDA clearance for screening AMD, according to a company news release. iPredict AI Eye Screening System provides fully automated age-related macular degener
- Euclid and Visionary Optics Announce Interactive Specialty Lens Forums in Cities Across the UShttps://modernod.com/news/euclid-and-visionary-optics-announce-interactive-specialty-lens-forums-in-cities-across-the-us/2481620/Euclid Vision is joining forces with Visionary Optics to host multiple specialty contact lens dinner discussions in cities around the US. The program,
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac
- Radius Announces Software Upgrade for Wearable Device for Perimetric Examinationshttps://modernod.com/news/radius-announces-perimeter-software-upgrade-for-wearable-device/2481518/Radius XR has launched its Radius 1.0 software release for perimetric examinations. Its interface is designed to assist eye care practices in delivering more comprehensive glaucoma management. Radius is a portable Vision Diagnostic and Patient Engagement system that combi
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb